Dual anti-HER2-directed therapies have emerged as the most beneficial neoadjuvant treatment option for patients with HER2-positive breast cancer, according to Frankie Ann Holmes, MD.
Frankie Ann Holmes, MD
Dual anti-HER2-directed therapies have emerged as the most beneficial neoadjuvant treatment option for patients with HER2-positive breast cancer, according to Frankie Ann Holmes, MD.
“Neoadjuvant directed therapy is seeing extremely high total pathological complete response rates, so for patients whose tumors are greater than 2 centimeters, or who are node positive, dual anti-HER2-directed therapy with trastuzumab and pertuzumab either with a taxane carboplatin backbone or, with the anthracycline cytoxan then taxane backbone, have shown to be very effective and are the optimal choices of therapy for those patients,” Holmes said in an interview withTargeted Oncologyfollowing her presentation on HER2-directed therapies at the 2016 International Congress on the Future of Breast Cancer.
In the NOAH trial,1looking at neoadjuvant chemotherapy with or without trastuzumab in women with HER2+ locally advanced or inflammatory breast cancer, there was a clear difference in the trastuzumab arm that showed the benefit of the combination therapy. The 5-year event-free survival rate was 58% (95% CI, 48-66) for the trastuzumab group and 43% (95% CI, 34-52) for the chemotherapy control group. Overall survival (OS) rates at 5 years were 74% (95% CI, 64-81) for the experimental group and 63% (95% CI, 53-71) for the control.
A number of clinical trials have explored lapatinib and trastuzumab in the neoadjuvant setting, including the GBG 44 phase III trial which compared lapatinib to trastuzumab in combination with an anthracycline-taxanebased chemotherapy regimen.2The lapatinib arm was found to be inferior, with a pathological complete response (pCR) rate of 22.7%, and had a higher toxicity profile than the trastuzumab arm, which showed a pCR rate of 30.3% (P= .04).
The NSABP B-41 trial explored lapatinib and trastuzumab separately as well as in combination, all with weekly paclitaxel following doxorubicin and cyclophosphamide.3The trastuzumab arm showed a pCR rate of 52.5% and the lapatinib arm had a similar rate of 53.2%. This same lack of difference between trastuzumab and lapatinib separately was seen in various other trials comparing the treatments, such as the smaller USOR 05-074 trial from Holmes et al.4
The combination arm of the NSABP B-41 showed a numerical difference with a pCR rate of 62% but a relatively low statistical rate (P= .095).3The combination arm of the USOR 05-074 trial also had a higher pCR rate of 74%, versus 54% for the trastuzumab arm and 45% for the lapatinib arm.4
“One of the findings that all of these studies has shown is that pCR does correlate with relapse-free survival and overall survival. In the hormone receptornegative subgroup … these are often the HER2-enriched subgroup, so they are more driven by HER2, there did seem to be an even more substantial benefit,” Holmes said during her presentation.
In the NSABP B-41 trial, the proportion of recurrence-free survival by breast pCR and hormone receptornegative status showed a rate of 89.2% pCR versus 64.1% non-pCR (P<.0001). OS rates were 93.1% for pCR and 71% for non-pCR.3
The NeoSphere phase II trial looked at neoadjuvant pertuzumab and trastuzumab in breast cancer.5The cohort that received pertuzumab, trastuzumab, and docetaxel (n = 107) showed the highest 5-year progression-free survival rate of 86% (95% CI, 77-91) versus 81% for the docetaxel plus trastuzumab cohort and 73% each for the pertuzumab plus trastuzumab and docetaxel plus pertuzumab arms.
The KRISTINE trial studied neoadjuvant ado-trastuzumab emtansine plus pertuzumab (T-DM1+P) versus trastuzumab, carboplatin, and docetaxel plus pertuzumab (TCH+P).6The TCH+P arm showed a higher pCR rate of 56% versus 44% for the T-DM1+P group. The difference was even greater in the hormone receptornegative subgroup, where TCH+P had a pCR rate of 73% versus 54% for the T-DM1+P cohort.
“One of the themes that we’ve heard … is that we have to identify who are these subgroups of patients who really don’t need the more aggressive chemotherapy,” Holmes said. Identifying those subgroups, however, would require a greater understanding of the gene signatures and biomarkers of HER2+ breast cancer.
References:
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More